1. Home
  2. Product Information

Product Information

Abundant and Potent Products

Our drug discovery research meets on-the-ground medical needs.
RaQualia's broad product portfolio ranges from development candidate compounds to products that are available in overseas markets. All of these products respond to both Japan's domestic medical needs and global opportunities. We analyze development candidate compounds forhighly-marketable, global target indications, responding to areas of high medical needs to build a sustainable product pipeline.

(As of August 10, 2017)

Japan Product Portfolio

Generic Name Class MOA Target Indication Latest Development Status
(Trade name in U.S.)

Anidulafungin

Echinocandin antifungal 1,3-β-D-glucan Synthesis Inhibitor Candida Infections Marketed
(Eraxis)

Dalbavancin

Glycopeptide anti-MRSA antibiotic Cell Wall Peptidoglycan Synthesis Inhibitor MRSA Infections Marketed
(Dalvance)

Global Product Portfolio

Program Compound Code Target Indication Development Stage Open Territory

Potassium-Competitive
Acid Blocker

Licensing Status
RQ-00000004 GERD(RE/NERD) Phase 1
(US/JPN)
WW (except Korea, China, Taiwan & Southeast Asia)

5-HT4 Partial Agonist

Licensing Status
RQ-00000010 Gastroparesis,
Functional Dyspepsia,
Chronic Constipation
Phase 1
(UK)
WW (except Korea, China, Taiwan, India & Southeast Asia)

5-HT2B Antagonist

RQ-00310941 D-IBS, IBD-remission Stage Symptoms Phase 1
(UK)
WW

Motilin Receptor Agonist

RQ-00201894 Gastroparesis,
Functional Dyspepsia,
Post-operative Ileus
Pre-Clinical WW
Ghrelin Receptor Agonist RQ-00433412 Cancer-related Anorexia/ Cachexia Syndrome Pre-Clinical WW
TRPM8 Blocker RQ-00434739 Neuropathic Pain (Chemotherapy-induced Cold Allodynia) Pre-Clinical WW

Page Top

Corporate Information
CEO Message
Company Overview
Vision, Management Principle and Culture
Quality Policy
Corporate Governance
Business Model
Origins of Our Corporate Name and Logo
Access
Press Release
Research & Development
Collaboration
Partnering in Research
What are Research Tools?
Research Tool Licensing
Product Information
Anidulafungin
Ziprasidone
Dalbavancin
Potassium-Competitive Acid Blocker
5-HT4 Partial Agonist
5-HT2B Antagonist
Motilin Receptor Agonist
Licensing Status
Shareholder and Investor Information
Vision, Management Principle and Culture
Corporate Governance
Outline of Securities Matters
IR Library
IR Calendar
Disclaimer
IR Related News
Understanding RaQualia Pharma! RaQualia FAQ
RaQualia's History
What does RaQualia Pharma do?
How Does RaQualia Earn Revenues?
What About Dividends?
What are RaQualia's strengths?
What Does the Future Hold for RaQualia Pharma?
Contributions to Society
Corporate Contributions
Contributions to the Community
Press Release
Topics